LY191145 is an N-alkylated glycopeptide antibiotic (the p-chlorobenzyl derivative of LY264826) with activity against vancomycin-susceptible and -resistant bacteria. Similar to vancomycin, LY191145 inhibited polymerization of peptidoglycan when muramyl pentapeptide served as a substrate but not when muramyl tetrapeptide was used, signifying a substrate-dependent mechanism of inhibition. LY264826 (A82846B) is a glycopeptide antibiotic with a structure similar to that of vancomycin but containing an additional amino sugar (4-epivancosamine) (28). The antibacterial activity of LY264826 is, on average, four-to eightfold greater than that of vancomycin against several gram-positive species (27, 31, 39) LY191145 is a semisynthetic N-alkylated derivative of LY264826 containing a p-chlorobenzyl side chain substituted at the amine position on the disaccharide moiety (Fig. 1) . Like its parent, LY191145 has enhanced antibacterial activity against vancomycin-susceptible bacteria (28, 31). However, the distinguishing characteristic of LY191145 is its activity against vancomycin-resistant bacteria. Whereas LY264826 is nominally more active than vancomycin against vancomycin-resistant bacteria, LY191145 has MICs of Յ4 g/ml for enterococcal isolates resistant to vancomycin and teicoplanin (31).
Vancomycin and other glycopeptide antibiotics inhibit cell wall peptidoglycan biosynthesis in susceptible bacteria by binding to key peptidoglycan intermediates (3, 30, 36, 38) . The heptapeptide portion of these agents forms a carboxylate bind- (36, 38) . LY264826 (A82846B) is a glycopeptide antibiotic with a structure similar to that of vancomycin but containing an additional amino sugar (4-epivancosamine) (28) . The antibacterial activity of LY264826 is, on average, four-to eightfold greater than that of vancomycin against several gram-positive species (27, 31, 39) . Despite the difference in activities, LY264826 and vancomycin share similar affinities for binding the D-Ala-D-Ala-containing tripeptide ligand N,NЈ-diacetyl-LLys-D-Ala-D-Ala (23) , and both agents inhibit the transglycosylation reaction in peptidoglycan biosynthesis (1) .
LY191145 is a semisynthetic N-alkylated derivative of LY264826 containing a p-chlorobenzyl side chain substituted at the amine position on the disaccharide moiety ( Fig. 1) . Like its parent, LY191145 has enhanced antibacterial activity against vancomycin-susceptible bacteria (28, 31) . However, the distinguishing characteristic of LY191145 is its activity against vancomycin-resistant bacteria. Whereas LY264826 is nominally more active than vancomycin against vancomycin-resistant bacteria, LY191145 has MICs of Յ4 g/ml for enterococcal isolates resistant to vancomycin and teicoplanin (31) .
Resistance to vancomycin results from the biosynthesis and utilization of a uridine diphospho (UDP)-MurNAc-pentadepsipeptide terminating in D-lactic acid instead of D-alanine (2, 13, 26) . Replacing the terminal D-alanine with D-lactic acid substitutes an ester for the usual carboxy-terminal amide linkage. The depsipeptidyl terminus can form only four hydrogen bonds with the carboxylate binding pocket of vancomycin rather than five, and binding is drastically curtailed (5, 37) . Substitution of the D-Ala-D-Ala terminus with a D-Ala-D-Lac terminus is necessary and sufficient to confer vancomycin-resistant peptidoglycan biosynthesis in VanA-type enterococci (2) .
An earlier study from this laboratory (1) demonstrated that exposure of vancomycin-resistant Enterococcus faecium to LY191145 led to the accumulation of UDP-MurNAc-pentadepsipeptide in the cytoplasm, consistent with inhibition of late-stage reactions in peptidoglycan biosynthesis. In experiments with vancomycin-resistant E. faecium permeabilized to nucleotide-linked peptidoglycan precursors, LY191145 inhibited incorporation of radioactivity from UDP-[ 14 C]GlcNAc into the peptidoglycan polymer when the UDP-MurNAc-pentadepsipeptide served as a substrate; inhibition led to the accumulation of lipid intermediate II in these experiments. These findings indicate that LY191145 inhibits the transglycosylation step of peptidoglycan biosynthesis in vancomycin-resistant bacteria.
It is important to know if the effects of LY191145 on transglycosylation in bacteria by using lactate-containing depsipeptide intermediates occur in a vancomycin-like, substrate-dependent fashion requiring interaction with D-Ala-D-Lac residues. We present evidence here that inhibition of peptidoglycan polymerization in vancomycin-resistant bacteria by LY191145 indeed requires interaction with D-Ala-D-Lac. Despite a poor binding affinity for D-Ala-D-Lac residues, interaction is made possible by a combination of dimerization and membrane anchoring.
MATERIALS AND METHODS
Bacterial strains. The following bacteria were used in this study: Aerococcus viridans ATCC 10400, Micrococcus luteus ATCC 9341, Bacillus megaterium ATCC 8245, and E. faecium 180 (VanA type) (32, 42) .
Antibiotics and peptidoglycan intermediates. Vancomycin, LY264826, LY191145, and nonglycopeptide antibiotics were obtained from Eli Lilly and Effects of antibiotics on peptidoglycan polymerization in a penicillin-insensitive assay. Incorporation of GlcNAc from UDP-[
14 C]GlcNAc into peptidoglycan polymer in the absence of cross-linking was measured in a penicillin-insensitive assay with a particulate membrane fraction prepared from A. viridans as described previously (12) . Polymerization was measured in reaction mixtures containing 0.167 mM either UDP-MurNAc-L-Ala-D-Glu-L-Lys-D-Ala-D-Ala or UDP-MurNAc-L-Ala-D-Glu-L-Lys-D-Ala as the nonradiolabeled substrate. Otherwise, reaction composition and assay conditions were as described before (1) .
D,D-Carboxypeptidase activity. The activity of highly purified D,D-carboxypeptidase from Actinomadura sp. strain R39 (kindly provided by P. Charlier, University Liège) was assayed by the procedures described by Messer and Reynolds (26) . Free D-alanine was measured by the D-amino acid oxidase-peroxidase procedure (16) . D-Lactic acid was quantitated by using D-lactate dehydrogenase as described previously (29) . was determined by affinity capillary electrophoresis by previously described methods (7, 8, 10) . Electrophoretic mobilities were measured with a P/ACE 5000 instrument (Beckman Instruments) equipped with a fused-silica capillary (57-cm [50 cm to the detector] by 75 m [inner diameter]). Mesityl oxide was used as a neutral marker. Analytes were detected at 214 nm. The run buffer was sodium phosphate; the ionic strength of buffer was varied from 20 to 75 mM, and pH was varied from 6.7 to 7.1 to optimize peak shape. Voltage was consequently varied from 30 kV for buffer with low ionic strength to 7.5 kV for buffer with high ionic strength; polarity was positive to negative. These changes provided more precise mobility measurements but did not significantly affect the magnitudes of the binding constants. The conditions result in migration of all species to the cathode and place an overall positive charge on each of the glycopeptides tested.
The effect of ligand concentration [L] on the mobility of a glycopeptide antibiotic ( G ) was determined as ⌬ G,L according to the following relation (10):
where l c is the total length of the capillary, l d is the length of the capillary to the detector, V is voltage, and t G and t EO are the migration times of the glycopeptide and neutral marker, respectively, in run buffer to which no ligand was added. Equation 1 corrects for the effects of [L] on electroosmotic flow (10) . Binding constants were estimated by Scatchard analysis by the following relation (10):
where K b represents the binding constant and ⌬ G,L max is the mobility of glycopeptide when it is saturated with ligand.
Dimerization of antibiotics.
Dimerization of glycopeptide antibiotics was measured by capillary zone electrophoresis and is based on the assumption that the electrophoretic mobility of a dimer differs from that of the monomer. The electrophoretic mobility ( obs ) of a glycopeptide was calculated as follows:
where the descriptors are the same as those given for equation 1. Plots of obs versus concentration for the glycopeptides used in this study reveal a first-order relationship between mobility and analyte concentration (see Fig. 4 ). Due to sample stacking and diffusion of analytes, it was necessary to determine the concentration of glycopeptide residing on the capillary by using peak height and the Lambert-Beer relationship. This was done by relating the peak height of the injected samples with the baseline absorbance determined for a series of standard concentrations added to the running buffer. In order to measure mobilities over the widest possible concentration range, wavelengths of 200, 214, and 280 nm were used for the lowest, intermediate, and highest concentrations, respectively. Linear standard curves were obtained for appropriate concentrations at each wavelength.
Dimerization constants (K dim ) were calculated from the data in Fig. 4 by the following relationship:
where d is the mobility of a sample containing all dimer, m is the mobility of a sample containing all monomer, and [G] t is the concentration of glycopeptide (monomer plus dimer). The derivation of equation 4 is based on the assumption that the electrophoretic mobility of an analyte that dimerizes is a function of the relative amounts of monomer and dimer present in the sample. The derivation of equation 4 and a detailed description of the capillary electrophoretic methodology will appear elsewhere (19 (17) . Vesicles were stored at Ϫ80ЊC until use. Binding of antibiotics was measured in duplicate 1-ml mixtures containing 10 mM Tris-HCl (pH 7.0), 20 mM MgCl 2 , 0.1 mg of membrane protein, and 0.15 mg of glycopeptide antibiotic. Binding was assayed at room temperature as the difference in concentration of free antibiotic in supernatants before and after centrifugation at 100,000 ϫ g for 40 min. Concentrations were determined by measuring UV absorbance at 280 nm and were adjusted for absorbance due to solubilization of membrane protein in the absence of antibiotic.
Preparation of protoplasts and measurement of antibiotic-induced lysis. Protoplasts of B. megaterium were prepared by lysozyme treatment as described by Roth et al. (40) . Protoplast formation was monitored by phase-contrast microscopy. Ninety percent of cells were converted to protoplasts after 8 to 10 min of incubation at 37ЊC. Antibiotic-induced lysis of protoplasts was assayed in 0.5 M sucrose; absorbance was monitored at 600 nm. Table 1 are mean values determined at several inhibitory concentrations of glycopeptide.
Antagonism of antibacterial activity by peptide ligands. Antagonism of the antibacterial activity by N,NЈ-diacetyl-L-Lys-D-Ala-D-Ala or N,NЈ-diacetyl-L-Lys-
Measurement of antagonism of antibacterial activity by an agar diffusion method is explained in the legend to Fig. 3 .
RESULTS AND DISCUSSION
Substrate-dependent inhibition of late-stage reactions in peptidoglycan biosynthesis. A particulate membrane fraction from A. viridans was used to compare the effects of vancomycin, LY264826, and LY191145 and nonglycopeptide cell wall inhibitors on the incorporation of GlcNAc from UDP-[
14 C] GlcNAc into peptidoglycan polymer by using UDP-MurNAcpentapeptide and UDP-MurNAc-tetrapeptide substrates. This assay measures the formation of un-cross-linked polymer; incorporation of radioactivity was unaffected by 250 g of penicillin G per ml (1) . Each of the glycopeptide antibiotics inhib- VOL. 41, 1997 INTERACTIONS OF LY191145 WITH CELL WALL PEPTIDESited incorporation when UDP-MurNAc-pentapeptide was used as the substrate (Table 1) , but there was essentially no inhibition by any of the glycopeptides when the UDP-MurNActetrapeptide substrate was used. By comparison, moenomycin, enduracidin, and amphomycin, which inhibit membrane-associated reactions in peptidoglycan biosynthesis by D-Ala-D-Alaindependent mechanisms (25, 41, 43) , inhibited incorporation, regardless of which substrate was used. Studies from this laboratory (1) indicate that inhibition of peptidoglycan polymerization by LY264826 and LY191145 occurs at the transglycosylation step, leading to accumulation of lipid intermediate II.
The results presented in Table 1 indicate that inhibition by LY264826 and LY191145 occurs by a substrate-dependent mechanism and imply that, in a manner similar to inhibition by vancomycin, inhibition by these agents in intact bacteria requires interaction with the terminal residues of lipid intermediate II. (Fig. 2) . All three glycopeptide agents inhibited release of D-Ala from UDP-MurNAc-pentapeptide with equal facility (Fig. 2A) ; at a 1:1 molar ratio of substrate to antibiotic, inhibition was close to 50% for all three compounds. None of the glycopeptide agents, however, affected the release of terminal D-Lac from UDP-MurNAc-pentadepsipeptide (Fig. 2B ). Ampicillin at 1 g/ml inhibited the carboxypeptidase-catalyzed hydrolysis of this substrate by 95%. The fact that LY191145 failed to inhibit release of D-Lac from the pentadepsipeptide substrate suggests that the activity of this agent against vancomycin-resistant enterococci cannot simply result from enhanced affinity for lactate-containing residues. b Antibiotic concentration ϭ 100 g/ml. No suppression
Affinities for binding D-Ala-D-
b Binding constants were determined by affinity capillary electrophoresis. Table 2 ). The antibacterial activities of LY264826 and LY191145 were suppressed by the same ligand, but 252-and 968-fold molar excesses were required to suppress inhibition by these two agents, respectively. An excess of the tridepsipeptide ligand N,NЈ-diacetyl-L-Lys-D-Ala-D-Lac did not noticeably antagonize any of the glycopeptides examined (Table 2 ). These results are very similar to those obtained in experiments designed to detect antagonism of the inhibition of peptidoglycan polymerization (1) .
Although the tridepsipeptide ligand did not antagonize in these experiments, reproducible antagonism by this ligand could be demonstrated qualitatively in an agar diffusion assay where zones of inhibition surrounding wells containing vancomycin or other glycopeptide were distorted by the presence of very high concentrations of the tridepsipeptide in adjacent wells (Fig. 3) . The small zone of inhibition surrounding the well containing LY191145 is due to poor diffusion of this compound in agar (18) . At a concentration of 1.5 mg per well, the tridepsipeptide clearly antagonized inhibition of M. luteus by both vancomycin and LY264826. Antagonism of inhibition by LY191145 was less obvious, but this is consistent with the observation that LY191145 required the greatest excess of N,NЈ-diacetyl-L-Lys-D-Ala-D-Ala to antagonize inhibition (Table 2). The results from the antagonism experiments (Table 2 and Fig. 3 ) taken together indicate that the glycopeptide antibiotics examined here can interact with both L-Lys-D-Ala-DAla and L-Lys-D-Ala-D-Lac residues and that these interactions are not necessarily the result of a simple bimolecular process.
Dimerization of glycopeptide antibiotics. Vancomycin and other glycopeptides can self-associate and form homodimers (9, 34, 44) . Vancomycin is relatively poor at dimer formation (9, 23, 34) ; by comparison, LY264826 and related glycopeptides have a much greater capacity to dimerize (9, 22, 23) . On the basis of results from nuclear magnetic resonance (NMR) and microbiological studies (4, 9, 11, 23, 24) , Williams and coworkers have proposed that dimerization can play an important role in determining antibacterial activity. The studies from that group showed that the affinities of certain glycopeptide antibiotics for cell wall analogs were enhanced by dimerization and that dimerization, in turn, was enhanced by the presence of the cell wall analogs. The findings revealed a subtle balance between dimerization and ligand binding in determining antibacterial activity (23) .
Dimerization of glycopeptide antibiotics can positively influence antibacterial activity by facilitating an intramolecular interaction between these agents and their targets at the cell surface (4, 24) . We examined dimerization of vancomycin, LY264826, and LY191145 using capillary zone electrophoresis (see Materials and Methods). The effect of concentration on mobility ( obs ) for each of the agents is illustrated in Fig. 4 ; the data indicate a first-order relationship between mobility and concentration and are consistent with the assumption that the electrophoretic mobilities of these compounds are a function of the relative amounts of monomer and dimer present in the sample. The range of concentrations of LY264826 and LY191145 (Fig. 4B ) eliciting a change in mobility was considerably lower than the range of vancomycin concentrations (Fig.  4A) needed to do the same. Dimerization constants (K dim ) were calculated from the data in Fig. 4 (9, 23) . The K dim values determined by either NMR or capillary zone electrophoresis were significantly lower than those estimated by a sedimentation equilibrium method (22) . These discrepancies are likely due to fundamental differences between the various methodologies with respect to concentration optima and the relative influences of pH and ionic strength on dimerization. More importantly, however, the K dim values for LY264826 and LY191145 given above exceed the K dim for vancomycin by factors of 99 and 168, respectively. Mackay et al. (23) have reported a similar difference in K dim values between LY264826 and vancomycin using NMR methods. A K dim for LY191145 has not been reported previously. The greater K dim values for LY264826 and LY191145 compared to that for vancomycin are consistent with the enhanced antibacterial activities (see footnote c in Table 2 ) and the increased molar excess of N,NЈ-diacetyl-L-Lys-D-Ala-D-Ala required to suppress the inhibitory effects of the two agents.
Interaction of glycopeptide antibiotics with bacterial membranes. Both LY264826 and LY191145 have enhanced activity against vancomycin-sensitive bacteria, but only LY191145 has significant activity against vancomycin-resistant bacteria (1, 31) . The ability of LY191145 to inhibit peptidoglycan biosynthesis, which is dependent on pentadepsipeptide-containing precursors, may be explained in part by strong dimerization. Williams and coworkers (4, 24) have proposed that the inhibitory activities of glycopeptides that contain a hydrophobic side chain (e.g., teicoplanin) may be enhanced further by virtue of the side chain anchoring the agent at the membrane-associated target site and facilitating an intramolecular interaction. Teicoplanin, which contains a C-10 acyl side chain, has been shown to interact with artificial liposomes (45, 46) . Both dimerization and membrane anchoring of glycopeptide antibiotics should increase the avidity of ligand binding at the target site without affecting simple binding affinities. An expectation from increased avidity would be decreased susceptibility to antagonism by tripeptide ligands.
Our comparison of LY264826 and LY191145 indicates that in addition to dimerization, membrane interactions may contribute to the activity of LY191145. The hydrophobic side chain on LY191145 confers the ability to bind to bacterial membranes (Fig. 5A ) and to lyse protoplasts (Fig. 5B) . Neither LY264826 nor vancomycin interacted with membranes or lysed protoplasts to the extent demonstrated by LY191145. Other derivatives of LY264826 containing a variety of alkyl and aryl side chains also interact with bacterial membranes (14) . We believe that rather than represent a secondary target, the membrane interactions reflect an ability of the side chains to serve as membrane anchors and contribute to intramolecular interactions and enhance inhibitory effects (45) .
Concluding remarks. The data presented here and in a previous publication (1) indicate that the antibacterial activity of LY191145 (and other N-alkylated derivatives of LY264826) against vancomycin-sensitive and vancomycin-resistant bacteria results from interaction with D-Ala-D-Ala-and D-Ala-D-Lac-containing residues of peptidoglycan intermediates, respectively, leading to inhibition of transglycosylation in peptidoglycan biosynthesis. LY191145 has poor affinity for binding D-Ala-D-Lac residues, but the combination of strong dimerization and membrane anchoring may be sufficient to facilitate intramolecular effects and effectively increase the binding affinities for peptidoglycan intermediates at the target site in bacteria resistant to vancomycin.
